ImClone Erbitux Use And Company Strategy
Editor's note: This story - which originally carried the headline "ImClone Erbitux Used By Nearly 80% Of Colorectal Cancer Patients" - contains an incorrect characterization of Erbitux usage in the overall colorectal cancer population. First-line colorectal cancer penetration for Bristol-Myers Squibb/ImClone's Erbitux (cetuximab) was in fact 4% in the fourth quarter of 2005. Second- and third-line penetration was 13% and 31%, respectively, ImClone said. Among the total number of patients using Erbitux, 82% were being treated for colorectal cancer.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth